Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project
Section snippets
How does this advance the field?
- •
Non-valvular atrial fibrillation (NVAF) increases risk of stroke and thromboembolism, but the role of pattern of NVAF in this prediction is less clear in contemporary ‘real world’ cohorts.
- •
This study confirms that pattern of NVAF does not add incremental value to stroke risk prediction in these patients.
- •
In patients with NVAF, age, previous stroke, heart failure and vascular disease are the strongest independent predictors of risk of stroke and thromboembolism, bleeding and all-cause mortality.
What are the clinical implications?
- •
In patients with atrial fibrillation, pattern of atrial fibrillation is not useful in predicting risk of stroke and thromboembolism, bleeding or all-cause mortality.
Study population
At the Centre Hospitalier Régional et Universitaire in Tours (France), all patients diagnosed with NVAF or atrial flutter by the department of cardiology between 2000 and 2010 were identified retrospectively (Fig. 2) [12]. Treatment at discharge was obtained by screening hospitalisation reports, and information on comorbidities was obtained from the computerised coding system.
For each patient, the CHADS2 [8] and CHA2DS2-VASc [9] scores were calculated. The CHADS2 score was the sum of points
Results
Of 8962 patients with AF, 7156 had NVAF (4176 paroxysmal, 376 persistent and 2604 permanent) and were included in the analysis (Fig. 1). Baseline characteristics are displayed in Table 1, with age-adjustment. Patients with permanent NVAF were older (p < 0.001) and even after age-adjustment, several differences remained between the different patterns of NVAF. Paroxysmal NVAF patients were more likely to be female (p < 0.001) whilst those with persistent NVAF were less likely to be associated with
Discussion
This large ‘real world’ cohort of patients with NVAF has shown that NVAF patients had different risk factor profiles based on pattern of NVAF. Compared with patients with paroxysmal NVAF, those patients with permanent NVAF had higher rates of stroke, stroke/TE, bleeding and death, whilst those with persistent NVAF had similar rates. However, in multivariate analyses, the pattern of NVAF was not associated with the risk of stroke/TE, bleeding or all-cause mortality and pattern of NVAF does
Conclusions
In this large ‘real world’ cohort of NVAF patients, we report statistically significant differences in rates of stroke/TE, bleeding and death based on patterns of NVAF. Only age, previous stroke, heart failure and vascular disease independently increased the risk of stroke/TE. Thus, pattern of NVAF may not provide additional value to stroke risk prediction in patients with NVAF.
Funding sources
This study has received no financial or material support.
Disclosures
Dr. Olesen has received travel grants from AstraZeneca and Boehringer Ingelheim. Dr. Taillandier has received funding for research from Sanofi Aventis. Dr. Lane has received funding for research, conference travel, and educational symposia from Bayer Healthcare, BMS/Pfizer and Boehringer Ingelheim, and is a member of the ACCP9 Writing Committee. Prof Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi Aventis, Biotronik, BMS/Pfizer, and Boehringher Ingelheim and has
Acknowledgements
LF, BL and ST made the primary contribution to data collection. AB, JBO, GYHL, DAL, and LF contributed to the study conception and design. AB performed the analyses. All authors contributed to interpretation of results, revising the manuscript critically for important intellectual content, and all approved the final manuscript. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.
References (26)
- et al.
A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study
Chest
(2012) - et al.
Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation. A nationwide database analysis
Atherosclerosis
(2011) - et al.
Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980–1999
Int J Cardiol.
(2005) - et al.
Improving stroke risk stratification in atrial fibrillation
Am J Med.
(2010) - et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation
Chest.
(2010) - et al.
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
J Am Coll Cardiol.
(2011) - et al.
Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project
Chest
(2012) - et al.
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators
J Am Coll Cardiol.
(2000) - et al.
ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy
J Am Coll Cardiol.
(2007) - et al.
Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation
Am Heart J.
(1986)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
Chest.
Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort
J Thromb Haemost.
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
Circulation.
Cited by (0)
- 1
Joint senior authors.